ClariVest Asset Management LLC raised its position in Omnicell Inc. (NASDAQ:OMCL) by 1.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 65,619 shares of the company’s stock after buying an additional 1,156 shares during the period. ClariVest Asset Management LLC’s holdings in Omnicell were worth $2,247,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the company. Emerald Advisers Inc. PA raised its position in shares of Omnicell by 266.2% in the second quarter. Emerald Advisers Inc. PA now owns 134,300 shares of the company’s stock worth $4,597,000 after buying an additional 97,630 shares during the period. Emerald Mutual Fund Advisers Trust raised its position in shares of Omnicell by 193.4% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 115,417 shares of the company’s stock worth $3,951,000 after buying an additional 76,074 shares during the period. Diversified Trust Co acquired a new position in shares of Omnicell during the second quarter worth approximately $216,000. Bank of Montreal Can acquired a new position in shares of Omnicell during the second quarter worth approximately $322,000. Finally, Thomson Horstmann & Bryant Inc. raised its position in shares of Omnicell by 2.0% in the second quarter. Thomson Horstmann & Bryant Inc. now owns 156,771 shares of the company’s stock worth $5,366,000 after buying an additional 3,021 shares during the period. Institutional investors own 95.26% of the company’s stock.
Omnicell Inc. (NASDAQ:OMCL) traded down 1.75% during midday trading on Tuesday, reaching $36.45. 48,019 shares of the company’s stock traded hands. The company’s 50-day moving average price is $37.88 and its 200-day moving average price is $34.16. The stock has a market cap of $1.32 billion, a P/E ratio of 92.51 and a beta of 0.58. Omnicell Inc. has a 52-week low of $25.06 and a 52-week high of $40.50.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.38 EPS for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.06. The firm had revenue of $175.60 million for the quarter, compared to analyst estimates of $170.89 million. Omnicell had a net margin of 2.36% and a return on equity of 10.41%. The business’s revenue for the quarter was up 55.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.28 EPS. On average, equities analysts predict that Omnicell Inc. will post $1.58 EPS for the current fiscal year.
A number of brokerages have recently commented on OMCL. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $46.00 price target on shares of Omnicell in a report on Tuesday, September 13th. Sidoti lowered shares of Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 price target on the stock. in a report on Thursday, September 8th. Zacks Investment Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 3rd. Finally, FBR & Co lifted their price target on shares of Omnicell from $40.00 to $41.00 and gave the stock an “outperform” rating in a report on Friday, July 29th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $38.13.
In related news, Director Gary S. Petersmeyer sold 2,000 shares of the stock in a transaction on Monday, September 12th. The shares were sold at an average price of $37.98, for a total transaction of $75,960.00. Following the transaction, the director now owns 17,987 shares of the company’s stock, valued at approximately $683,146.26. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Jorge R. Taborga sold 10,023 shares of the stock in a transaction on Friday, July 29th. The shares were sold at an average price of $40.00, for a total transaction of $400,920.00. Following the transaction, the vice president now directly owns 49,073 shares in the company, valued at approximately $1,962,920. The disclosure for this sale can be found here. 3.75% of the stock is currently owned by insiders.
Omnicell Company Profile
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.